Search Results
Mar 19, 2026, 16:00 ET Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results
chondrosarcoma to the U.S. Food and Drug Administration ("FDA") early in the second quarter of 2026;We plan to announce progression-free survival ("PFS") data for the Phase 1/2 colorectal cancer expansion cohort in the second quarter of 2026; andWe plan to meet with the FDA to discuss accelerated
More news about: Inhibrx Biosciences, Inc.
Mar 19, 2026, 10:00 ET 97% Recovery. Fully Permitted. 12 Kilometers From a 20-Million-Ounce Deposit. And Nobody's Talking About It.
therefore is not independent of the Company. Cautionary Note on Production Decision: Although Imwelo has been the subject of JORC-compliant PEA, PFS and updated PFS work, these foreign-code studies are not current under NI 43-101. The Company has not completed a feasibility study on Imwelo that establishes
More news about: USA News Group
Mar 18, 2026, 11:39 ET CakeClub Launches U.S.-Based Cash-Flow Visibility App Focused on Financial Awareness
investment, portfolio management, or wealth management services."Our focus is clarity," said Al Zdenek, Executive Chair of CakeClub® and a CPA, PFS, and author of Master Your Cash Flow, whose work on cash-flow awareness informed the app's educational framework."When people can clearly see how money
More news about: CakeClub
Mar 18, 2026, 10:27 ET Kelun-Biotech to Present the Final OS Analysis of Sacituzumab Tirumotecan (Sac-TMT) from the OptiTROP-Lung03 Study
achieved statistically significant and clinically meaningful improvements in progression-free survival (PFS) and overall survival (OS) compared to docetaxel——the hazard ratio (HR) for BICR-assessed PFS was 0.30 (95% CI: 0.20–0.46, one-sided p<0.001) and HR for OS was 0.49 (95% CI: 0.27–0.88, one-sided
More news about: Kelun-Biotech
Mar 18, 2026, 10:00 ET High-Margin Mining: How the Smart Money Is Navigating the New Gold Supercycle
therefore is not independent of the Company. Cautionary Note on Production Decision: Although Imwelo has been the subject of JORC-compliant PEA, PFS and updated PFS work, these foreign-code studies are not current under NI 43-101. The Company has not completed a feasibility study on Imwelo that establishes
More news about: USA News Group
Mar 18, 2026, 07:58 ET Biotheryx Announces First Patient Dosed in the Dose Expansion Phase of BTX-9341-101 for the Treatment of HR+/HER2- Breast Cancer
Rate (ORR), with key secondary endpoints including the measurement of investigator-assessed Clinical Benefit Rate (CBR) and Progression Free Survival (PFS)."We are pleased to have dosed the first patient in the dose expansion portion of our clinical trial evaluating BTX-9341 in combination with fulvestrant."
More news about: Biotheryx, Inc.
Mar 17, 2026, 10:53 ET DELIVERING THE FUTURE
time. By using electromechanical devices like PRIME NEXUS™, companies will be able to use different primary packaging containers from 1 mL PFS, 2 mL PFS and now 5 mL PFS, but still ensure that patients receive a complete injection within a targeted period.Portal's latest reusable electrotechnical autoinjector,
More news about: Portal Instruments, Inc.
Mar 16, 2026, 16:50 ET Cypherpunk Reports Full Year 2025 Financial Results
statistically significant benefit on overall response rate ("ORR"), progression-free survival ("PFS"), and Overall Survival ("OS") in patients with high levels of DKK1, along with a positive trend on ORR and PFS in the full intent-to-treat population.Across the DKK1-high (upper quartile) patients
More news about: Cypherpunk Technologies Inc.
Mar 10, 2026, 20:38 ET Denison Reports Financial and Operational Results for 2025 and Final Investment Decision to Construct the Phoenix ISR Uranium Mine
Saskatchewan. In mid-2023, the Phoenix FS was completed for the Phoenix ISR mining operation, and an update to the 2018 Pre-Feasibility Study ("2018 PFS") was completed for the Gryphon deposit as a conventional underground mining operation (the "Gryphon Update"). Based on the respective studies, both deposits
More news about: Denison Mines Corp.
Mar 10, 2026, 07:30 ET ADC Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Operational Update
actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to: the timing of the PFS events and topline data release for LOTIS-5 and the results of the trial, the timing for the sBLA submission, acceptance and outcome of review of the
More news about: ADC Therapeutics SA
Mar 10, 2026, 07:02 ET Zemcelpro® (dorocubicel) Positive Results in High- and Very High-Risk Blood Cancers to be Reported at the EBMT 2026 Annual Meeting
At 24 months post-transplant, overall survival (OS), progression-free survival (PFS) and relapse-free survival (RFS) were 63.7%, 57.0% and 60%, respectively, among Zemcelpro® (dorocubicel)-treated patients. The cumulative incidences
More news about: ExCellThera
Mar 10, 2026, 07:02 ET Zemcelpro® (dorocubicel) Positive Results in High- and Very High-Risk Blood Cancers to be Reported at the EBMT 2026 Annual Meeting
At 24 months post-transplant, overall survival (OS), progression-free survival (PFS) and relapse-free survival (RFS) were 63.7%, 57.0% and 60%, respectively, among Zemcelpro® (dorocubicel)-treated patients. The cumulative incidences
More news about: ExCellThera
Mar 10, 2026, 07:02 ET Zemcelpro® (dorocubicel) : des résultats positifs dans les cancers du sang à haut et très haut risque seront présentés lors du congrès annuel 2026 de l'EBMT
À 24 mois après la greffe, la survie globale (OS), la survie sans progression (PFS) et la survie sans rechute (RFS) étaient respectivement de 63,7 %, 57,0 % et 60 % chez les patients traités par Zemcelpro® (dorocubicel). Les incidences
More news about: ExCellThera
Mar 10, 2026, 06:15 ET Uranium Energy Corp Reports Results for Second Quarter of Fiscal 2026
quarter.Roughrider Pre-Feasibility Progressing: Core drilling is over 30% complete to support the pre-feasibility study ("PFS") for the world class Roughrider Project in the Athabasca Basin of Saskatchewan, Canada. At the same time, UEC is working with SaskPower towards
More news about: Uranium Energy Corp
Mar 09, 2026, 07:30 ET ImmunityBio Announces Resubmission of Supplemental BLA to the FDA for ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC with Papillary Disease Following Agency Review of Additional Data
ANKTIVA plus BCG demonstrated a 96.0% disease-specific survival (DSS) rate at 36 months, with median DSS not yet reached. Progression-free survival (PFS) was 94.9% at 12 months and 83.1% at 36 months, indicating durable prevention of progression to muscle-invasive disease. Bladder preservation remained
More news about: ImmunityBio
Mar 09, 2026, 02:28 ET Leads Biolabs' Opamtistomig (LBL-024) Enrolls First ESCC Patient, Exploring Dual PD-L1/4-1BB Mechanism for Superior Survival Benefits in China's High-Incidence Cancer
prognosis. Although immune checkpoint inhibitors combined with chemotherapy have improved objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) compared to chemotherapy alone, median OS remains only 12-17 months. This underscores the limitations of current treatment
More news about: Leads Biolabs
Mar 06, 2026, 08:00 ET U.S. FDA Approves TECVAYLI® in Combination with DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma
have received at least one prior line of therapy. TECVAYLI® in combination with DARZALEX FASPRO® demonstrated statistically significant improvements in PFS and OS in patients with RRMM compared to standard treatment after a median follow-up of three years in patients with RRMM. Results show an 83% reduction
More news about: Halozyme Therapeutics, Inc.
Mar 06, 2026, 07:03 ET CARsgen Therapeutics Announces 2025 Annual Results
orally presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. Satri-cel demonstrated significant progression-free survival (PFS) improvement and a clinically meaningful overall survival (OS) benefit with a manageable safety profile, compared to standard therapy.The research
More news about: CARsgen Therapeutics
Mar 05, 2026, 15:55 ET Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI® plus DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early as Second Line
Options"This new treatment option can redefine how we approach RRMM treatment by giving healthcare providers a regimen with improvement in PFS and OS and a well-characterized safety profile," said Dr. Luciano J. Costa, Professor of Multiple Myeloma and Director of the Multiple Myeloma Research
More news about: Johnson & Johnson
Mar 05, 2026, 06:30 ET U.S. GoldMining Appoints Imola Götz as VP, Project Development
NPV5% of over $2.0 billion and initial payback of just over two years, the Company is advancing towards a possible pre-feasibility study ("PFS"). We are very pleased to welcome Imola to the team as we look to accelerate our ongoing mine engineering and permitting studies. It's an exciting time
More news about: U.S. GoldMining Inc.
Mar 04, 2026, 21:26 ET Cadonilimab Achieves 100% 24-Month OS in Complete Responders in R/M Cervical Cancer Based on Long-Term Phase II Results
survival (PFS) was also not reached, with a 12-month PFS rate of 84.6% (nominal p < 0.0001).In patients achieving partial response (PR), the median OS remained unreached (NR), with a 24-month OS rate of 63% (nominal p = 0.0002). The median PFS was 11.17 months, and the 12-month PFS rate was
More news about: Akeso, Inc.
Mar 04, 2026, 09:15 ET Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR™ (E7777) Dosing Prior to Commercial CAR‑T Therapy in High‑Risk Diffuse Large B‑Cell Lymphoma
response rate (ORR) was 86% at one month, including 57% complete responses (CR) and 29% partial responses (PR);One‑year progression‑free survival (PFS) was 77% (95% CI: 43–92%);One‑year overall survival (OS) was 84% (95% CI: 49–96%);A single LYMPHIR dose resulted in depletion of circulating
More news about: Citius Oncology, Inc.
Mar 04, 2026, 07:00 ET Defense Metals Receives Conditional Approval for up to C$1.88 Million in Funding for Wicheeda Rare Earth Elements Clean Energy and Transportation Infrastructure Project
energy-efficient technologies.The PFS for the Wicheeda Rare Earth Element Project is preliminary in nature and includes numerous assumptions regarding metallurgy, capital and operating costs, and market conditions.Mineral reserves and the economic outcomes projected in the PFS are subject to significant
More news about: Defense Metals Corp.
Mar 03, 2026, 07:15 ET ADC Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call on March 10, 2026
timing, publication and outcome of the full LOTIS-7 trial, compendia inclusion and regulatory strategy and the commercial opportunity; the timing of the PFS events and topline data release for LOTIS-5 and the results of the trial, the timing for the sBLA submission and full FDA approval; the Company's ability
More news about: ADC Therapeutics SA
Mar 02, 2026, 16:05 ET ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
timing, publication and outcome of the full LOTIS-7 trial, compendia inclusion and regulatory strategy and the commercial opportunity; the timing of the PFS events and topline data release for LOTIS-5 and the results of the trial, the timing for the sBLA submission and full FDA approval; the Company's ability
More news about: ADC Therapeutics SA